Pandemic Watch
Zaire ebolavirus vs Sudan ebolavirus
A factual side-by-side comparison of two ebolavirus species: Zaire ebolavirus and Sudan ebolavirus. Reservoir biology, geographic distribution, clinical course, case-fatality rate, and outbreak history.
Discovery and history
Zaire ebolavirus
Zaire ebolavirus was first isolated in 1976 during a near-simultaneous pair of outbreaks: one near the Ebola River in northern Zaire (now the Democratic Republic of the Congo), and another in southern Sudan that was initially assumed to be the same virus but turned out to be a distinct species (now Sudan ebolavirus). The Zaire outbreak in Yambuku, traced largely to a Catholic mission hospital that re-used unsterilized needles for antenatal injections, killed 280 of 318 reported cases — an 88 percent case-fatality rate that set the early reputation of Ebola as among the most lethal known viral infections. The virus was named for the river to avoid stigmatizing the village itself.
Sudan ebolavirus
Sudan ebolavirus was first identified in 1976 in cotton-factory workers in Nzara and Maridi, southern Sudan (now South Sudan), in an outbreak that occurred almost simultaneously with the Yambuku Zaire ebolavirus outbreak across the border. The two events were initially assumed to share a virus until subsequent serological and genetic work confirmed they were distinct species. The Nzara cluster killed 151 of 284 reported cases (53 percent case-fatality) and established that the Ebola family contained multiple genetically distinct members.
Reservoir and ecology
Zaire ebolavirus
The natural reservoir is strongly suspected but not definitively confirmed to be fruit bats of the family Pteropodidae — in particular Hypsignathus monstrosus (hammer-headed bat), Epomops franqueti (Franquet's epauletted fruit bat), and Myonycteris torquata (little collared fruit bat). Serological evidence of ebolavirus exposure in these species has been documented across the Congo Basin and West Africa. Spillover into humans is thought to occur both directly (contact with bat saliva, urine, or droppings, often via fruit bats roosting in trees or buildings) and indirectly (hunting and butchering primates or other forest mammals that have themselves been infected by bat material). Once a spillover occurs, the human-to-human transmission cycle takes over and the wildlife reservoir is no longer epidemiologically relevant for the duration of the outbreak.
Sudan ebolavirus
Like other ebolavirus species, the natural reservoir is suspected to be fruit bats of family Pteropodidae, though definitive confirmation for Sudan ebolavirus specifically has been elusive. Surveys of bat populations in Uganda and South Sudan have detected ebolavirus antibodies in several species; isolation of live virus has been rare. The spillover pathway is presumed to involve direct or indirect contact with infected bats or with primates and other forest mammals exposed to bat material — consistent with the pattern documented for Zaire ebolavirus.
Clinical course
Zaire ebolavirus
Ebola virus disease begins after an incubation period of two to twenty-one days (typically eight to ten) with sudden fever, severe headache, myalgia, fatigue, and pharyngitis. Within several days patients develop vomiting, watery diarrhea, abdominal pain, and a maculopapular rash. The volume of fluid loss is extreme — patients with severe disease can lose five to ten liters per day to diarrhea, driving profound electrolyte derangements and hypovolemic shock. Hemorrhagic manifestations (petechiae, conjunctival hemorrhage, bleeding from venipuncture sites, gastrointestinal bleeding) appear in roughly half of severe cases. Death, when it occurs, is typically between days seven and sixteen and is driven by hemorrhagic shock, multi-organ failure, or both. Case-fatality has ranged from 44 percent in the 2014-2016 West Africa epidemic to 88 percent in early outbreaks — the variability tracks closely with access to early supportive care, particularly aggressive intravenous fluid and electrolyte replacement.
Sudan ebolavirus
The clinical course mirrors Zaire ebolavirus: a 2-21 day incubation, sudden onset of fever and myalgia, gastrointestinal phase with severe vomiting and diarrhea, and hemorrhagic manifestations in roughly half of severe cases. Aggressive intravenous fluid replacement is again the foundation of supportive care. Case-fatality has ranged from 41 percent (Kibaale 2012) to 71 percent (Nzara 1976), with the recent 2022 Mubende outbreak landing around 47 percent. The absence of licensed therapeutics for Sudan virus means that outcomes still depend largely on the quality and timing of supportive care.
Notable outbreaks
Zaire ebolavirus
The 1976 Yambuku outbreak in Zaire (318 cases, 280 deaths) was the original Ebola event. The 1995 Kikwit outbreak in DRC (315 cases, 254 deaths) brought Ebola into wider international consciousness and triggered the first systematic infection-control response by an international team. The 2000 Gulu outbreak in northern Uganda spread to healthcare workers and produced 425 cases — although that outbreak was Sudan ebolavirus rather than Zaire. The defining Zaire ebolavirus event is the 2014 to 2016 West Africa epidemic: 28,616 reported cases, 11,310 deaths across Guinea, Sierra Leone, and Liberia, and the first ebolavirus exportation to the United States and Europe. The 2018 to 2020 North Kivu outbreak in DRC was the second-largest Ebola event ever (3,481 cases, 2,299 deaths) and saw the first widespread deployment of the rVSV-ZEBOV vaccine under a ring-vaccination strategy.
Sudan ebolavirus
The 2000 Gulu outbreak in northern Uganda (425 cases, 224 deaths) remains the largest Sudan ebolavirus event. It also shaped modern Ebola response: the WHO Global Outbreak Alert and Response Network deployed at scale for the first time, and ring infection control around Lacor Hospital became a template for subsequent outbreaks. The 2022 Mubende outbreak in central Uganda produced 164 confirmed cases and 55 deaths over four months and prompted the first ring-vaccination trial of a candidate Sudan virus vaccine. The earliest 1976 Nzara/Maridi outbreak, occurring within weeks of the parallel Zaire outbreak across the border, was the discovery event for the species.
Prevention
Zaire ebolavirus
The licensed vaccine Ervebo (rVSV-ZEBOV) protects against Zaire ebolavirus and is the cornerstone of outbreak response. WHO's ring-vaccination strategy — immunizing contacts of confirmed cases and contacts of contacts within days of identification — has interrupted transmission chains in DRC outbreaks since 2018. Beyond vaccination, infection prevention and control in healthcare facilities (PPE, isolation, dedicated Ebola treatment units) and safe-burial protocols (avoiding traditional washing of bodies, which exposes funeral attendees to the virus) are the two highest-impact non-pharmaceutical interventions. Survivor follow-up matters as well: Zaire ebolavirus persists in immune-privileged sites (eye, central nervous system, testis) for months in some survivors and can cause flare cases and onward transmission long after the original outbreak is declared over.
Sudan ebolavirus
No licensed vaccine or therapeutic exists specifically for Sudan ebolavirus, which is the defining gap in the current outbreak-response toolkit. The candidate vaccines cAd3-SUDV (chimpanzee adenovirus-vectored) and SVABCV-VR (chimpanzee adenovirus + MVA prime-boost) have shown safety and immunogenicity in phase I/II trials and have been deployed under ring-vaccination protocols during the 2022 Uganda Mubende outbreak and the current 2026 PHEIC. Outside of vaccination, the same infection prevention and control principles apply as for Zaire virus: rigorous PPE in healthcare settings, safe-burial protocols, contact tracing, and dedicated Ebola treatment units.
Full strain profiles: Zaire ebolavirus · Sudan ebolavirus. For the broader disease guide, see ebola.
